HRP20010399A2 - Reactive crystallization method to improve particle size - Google Patents
Reactive crystallization method to improve particle size Download PDFInfo
- Publication number
- HRP20010399A2 HRP20010399A2 HR20010399A HRP20010399A HRP20010399A2 HR P20010399 A2 HRP20010399 A2 HR P20010399A2 HR 20010399 A HR20010399 A HR 20010399A HR P20010399 A HRP20010399 A HR P20010399A HR P20010399 A2 HRP20010399 A2 HR P20010399A2
- Authority
- HR
- Croatia
- Prior art keywords
- product
- reactive
- crystallization
- jet streams
- jet
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims description 40
- 238000002425 crystallisation Methods 0.000 title claims description 34
- 238000000034 method Methods 0.000 claims description 67
- 230000008025 crystallization Effects 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 31
- 239000012048 reactive intermediate Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000003513 alkali Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical group C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 13
- 239000000543 intermediate Substances 0.000 claims description 12
- 229960000607 ziprasidone Drugs 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960004740 voriconazole Drugs 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000010899 nucleation Methods 0.000 claims description 6
- 230000006911 nucleation Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- JQSHBVHOMNKWFT-UHFFFAOYSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2C2CC1CNC2 JQSHBVHOMNKWFT-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 238000002156 mixing Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- -1 voriconazole salt R-( –)-camphorsulfonic acids Chemical class 0.000 description 7
- 239000012296 anti-solvent Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- AMYMCJHOGKVJHB-CRFUWKMFSA-N (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol [(1R,4S)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C.C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F AMYMCJHOGKVJHB-CRFUWKMFSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/02—Crystallisation from solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/20—Jet mixers, i.e. mixers using high-speed fluid streams
- B01F25/23—Mixing by intersecting jets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J14/00—Chemical processes in general for reacting liquids with liquids; Apparatus specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/18—Stationary reactors having moving elements inside
- B01J19/1806—Stationary reactors having moving elements inside resulting in a turbulent flow of the reactants, such as in centrifugal-type reactors, or having a high Reynolds-number
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/26—Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00049—Controlling or regulating processes
- B01J2219/00051—Controlling the temperature
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00049—Controlling or regulating processes
- B01J2219/00051—Controlling the temperature
- B01J2219/00074—Controlling the temperature by indirect heating or cooling employing heat exchange fluids
- B01J2219/00087—Controlling the temperature by indirect heating or cooling employing heat exchange fluids with heat exchange elements outside the reactor
- B01J2219/00101—Reflux columns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00049—Controlling or regulating processes
- B01J2219/00164—Controlling or regulating processes controlling the flow
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20762900P | 2000-05-26 | 2000-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010399A2 true HRP20010399A2 (en) | 2002-12-31 |
Family
ID=22771343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010399A HRP20010399A2 (en) | 2000-05-26 | 2001-05-24 | Reactive crystallization method to improve particle size |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6558435B2 (ko) |
| EP (1) | EP1157726A1 (ko) |
| JP (1) | JP2002028475A (ko) |
| KR (1) | KR100408949B1 (ko) |
| CN (1) | CN1183989C (ko) |
| AP (1) | AP1321A (ko) |
| AR (1) | AR029099A1 (ko) |
| AU (1) | AU775613B2 (ko) |
| BG (1) | BG105518A (ko) |
| BR (1) | BR0102129A (ko) |
| CA (1) | CA2349136A1 (ko) |
| CZ (1) | CZ20011726A3 (ko) |
| DZ (1) | DZ3075A1 (ko) |
| EA (1) | EA003261B1 (ko) |
| EC (1) | ECSP014083A (ko) |
| EE (1) | EE200100284A (ko) |
| GE (1) | GEP20043173B (ko) |
| GT (1) | GT200100095A (ko) |
| HK (1) | HK1038896B (ko) |
| HR (1) | HRP20010399A2 (ko) |
| ID (1) | ID30368A (ko) |
| IL (1) | IL143227A (ko) |
| IS (1) | IS5950A (ko) |
| MA (1) | MA25321A1 (ko) |
| NO (1) | NO20012571L (ko) |
| NZ (1) | NZ511966A (ko) |
| OA (1) | OA11719A (ko) |
| PA (1) | PA8517001A1 (ko) |
| PE (1) | PE20020149A1 (ko) |
| PL (1) | PL347736A1 (ko) |
| SG (1) | SG96223A1 (ko) |
| SK (1) | SK6882001A3 (ko) |
| SV (1) | SV2001000464A (ko) |
| TN (1) | TNSN01075A1 (ko) |
| TR (1) | TR200101453A3 (ko) |
| TW (1) | TWI236930B (ko) |
| YU (1) | YU34501A (ko) |
| ZA (1) | ZA200104207B (ko) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229867B1 (en) * | 2001-05-14 | 2014-10-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| WO2003045394A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| US20040005256A1 (en) * | 2002-04-29 | 2004-01-08 | Chenkou Wei | Crystallization system utilizing atomization |
| PL373959A1 (en) * | 2002-05-10 | 2005-09-19 | Bristol-Myers Squibb Company | Crystallization system using homogenization |
| US20040098839A1 (en) * | 2002-11-27 | 2004-05-27 | Pfizer Inc. | Crystallization method and apparatus using an impinging plate assembly |
| AU2003300814A1 (en) | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
| WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
| KR100880279B1 (ko) * | 2003-06-03 | 2009-01-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 지프라시돈 염산염 및 그의 제조 방법 |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| EP1628973A2 (en) | 2003-10-24 | 2006-03-01 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| US20050163858A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Ziprasidone formulations |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US7396932B2 (en) * | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US7314516B2 (en) * | 2004-12-29 | 2008-01-01 | Five Star Technologies, Inc. | Hydrodynamic cavitation crystallization device and process |
| US20060160841A1 (en) * | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
| DE102005053862A1 (de) * | 2005-11-04 | 2007-05-10 | Pharmasol Gmbh | Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel |
| CA2640922A1 (en) * | 2006-02-01 | 2007-11-22 | Medichem, S.A. | Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof |
| SG172700A1 (en) * | 2006-04-28 | 2011-07-28 | Schering Corp | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| US8420122B2 (en) * | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
| KR100850011B1 (ko) * | 2007-03-19 | 2008-08-04 | 희성금속 주식회사 | 초음파 화학적 반응에 의한 산화 주석 분말의 제조 방법 및ｉｔｏ 타겟재의 제조 방법 |
| KR100850010B1 (ko) * | 2007-03-19 | 2008-08-04 | 희성금속 주식회사 | 초음파 화학적 반응에 의한 산화 인듐 분말의 제조방법 및ｉｔｏ 타겟재의 제조방법 |
| MX2009013499A (es) * | 2007-06-22 | 2010-01-18 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
| JP2010530892A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
| CN101801348A (zh) * | 2007-06-22 | 2010-08-11 | 百时美施贵宝公司 | 含有阿扎那韦的压片组合物 |
| PT2170292E (pt) * | 2007-06-22 | 2014-03-06 | Bristol Myers Squibb Holdings Ireland | Composições de comprimido contendo atazanavir |
| WO2009032558A2 (en) * | 2007-08-31 | 2009-03-12 | Dr. Reddy's Laboratories Ltd. | Preparation of ziprasidone hydrochloride monohydrate |
| WO2009101185A2 (en) * | 2008-02-15 | 2009-08-20 | Medichem, S.A. | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE |
| WO2009111623A2 (en) * | 2008-03-06 | 2009-09-11 | Dr. Reddy's Laboratories Ltd. | Amorphous varenicline tartrate |
| US8187554B2 (en) * | 2008-04-23 | 2012-05-29 | Microfluidics International Corporation | Apparatus and methods for nanoparticle generation and process intensification of transport and reaction systems |
| US8039620B2 (en) | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
| US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
| US8219740B2 (en) * | 2008-06-25 | 2012-07-10 | International Business Machines Corporation | Flash sector seeding to reduce program times |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| DE102009008478A1 (de) | 2009-02-11 | 2010-08-19 | PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH | Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren |
| RU2012102052A (ru) | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
| EP2470529B1 (en) * | 2009-12-30 | 2014-11-19 | Medichem, S.A. | A 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivative for pharmaceutical use, and the use of a 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivate with substantially undefined crystal shape for preparing said 1-(1h-1,2,4-triazol-1-yl)butan-2-ol derivative |
| EP2545054A1 (en) * | 2010-03-09 | 2013-01-16 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| EA025562B1 (ru) * | 2010-03-22 | 2017-01-30 | Инстилло Гмбх | Способ для получения микрочастиц или наночастиц и устройство для его осуществления |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| EP2621620B1 (en) | 2010-09-28 | 2016-04-06 | Dow Global Technologies LLC | Reactive flow static mixer with cross-flow obstructions and method for mixing |
| US10350556B2 (en) | 2011-01-07 | 2019-07-16 | Microfluidics International Corporation | Low holdup volume mixing chamber |
| US9079140B2 (en) | 2011-04-13 | 2015-07-14 | Microfluidics International Corporation | Compact interaction chamber with multiple cross micro impinging jets |
| US9199209B2 (en) | 2011-04-13 | 2015-12-01 | Microfluidics International Corporation | Interaction chamber with flow inlet optimization |
| US9732068B1 (en) | 2013-03-15 | 2017-08-15 | GenSyn Technologies, Inc. | System for crystalizing chemical compounds and methodologies for utilizing the same |
| PL3119489T3 (pl) * | 2014-03-19 | 2022-01-17 | Basf Se | Sposób oddzielania substancji z roztworu |
| CN104843745B (zh) * | 2015-04-27 | 2016-08-24 | 青海国泰盐湖化肥有限公司 | 一种复分解法硝酸钾产品粒度的控制方法 |
| CN106853295A (zh) * | 2015-12-09 | 2017-06-16 | 北大方正集团有限公司 | 一种基于膜分散的结晶方法 |
| CN108264457A (zh) * | 2017-01-04 | 2018-07-10 | 辽宁药联制药有限公司 | 一种醋酸钾的制备方法 |
| EP3664785A4 (en) | 2018-06-22 | 2022-01-12 | Delphi Scientific, LLC | APPARATUS, SYSTEMS, AND METHODS FOR CONTINUOUS MANUFACTURING OF NANOMATERIALS AND HIGH-PURITY CHEMICALS |
| CN111346397B (zh) * | 2020-03-11 | 2022-03-29 | 天津大学 | 适用于溶析结晶或反应结晶的加料设备 |
| CN113980020B (zh) * | 2021-11-22 | 2023-05-09 | 浙江车头制药股份有限公司 | 一种酒石酸伐尼克兰晶型的制备方法 |
| CN114130324A (zh) * | 2021-12-01 | 2022-03-04 | 沈阳铝镁设计研究院有限公司 | 一种蛟吸增效分解系统 |
| CN115253367A (zh) * | 2022-08-31 | 2022-11-01 | 浙江新和成股份有限公司 | 一种布洛芬微晶的生产装置及结晶方法和产品 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3330445A1 (de) * | 1983-08-24 | 1985-03-21 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von als feststoffe anfallenden chemischen verbindungen aus fluessigen ausgangsstoffen |
| US4675194A (en) * | 1986-03-03 | 1987-06-23 | Reaction Technology, Inc. | Sonic process for converting proteinaceous raw materials in situ into semi-solid food products |
| SE8700213L (sv) | 1987-01-21 | 1988-07-22 | Nobel Kemi Ab | Sett att framstella kristallina substanser |
| CH671166A5 (en) | 1987-07-01 | 1989-08-15 | Fershan Holding S A | Crystallisation nuclei formation - by turbulising soln. and applying mechanical energy to form nucleation sites |
| JP3282731B2 (ja) | 1990-06-15 | 2002-05-20 | メルク エンド カムパニー インコーポレーテッド | 結晶の構造および大きさを改良する結晶化方法 |
| US5143965A (en) * | 1990-12-26 | 1992-09-01 | The Dow Chemical Company | Magnesium hydroxide having fine, plate-like crystalline structure and process therefor |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| US5853691A (en) * | 1993-08-10 | 1998-12-29 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On The Behalf Of The University Of Oregon | Silver halides of altered crystal habit or morphology and methods for producing same |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4431872C1 (de) | 1994-09-07 | 1996-01-11 | Santrade Ltd | Anwendung von Ultraschall bei der Verfestigung von Schmelzen oder übersättigten Lösungen auf Förderbändern oder Aufnahmetrommeln |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| GB9624615D0 (en) | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Chrystallisation process |
| GB9703673D0 (en) | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
-
2001
- 2001-05-16 CZ CZ20011726A patent/CZ20011726A3/cs unknown
- 2001-05-16 YU YU34501A patent/YU34501A/sh unknown
- 2001-05-16 TW TW090111673A patent/TWI236930B/zh not_active IP Right Cessation
- 2001-05-17 BG BG105518A patent/BG105518A/xx unknown
- 2001-05-17 IL IL14322701A patent/IL143227A/xx not_active IP Right Cessation
- 2001-05-18 SK SK688-2001A patent/SK6882001A3/sk unknown
- 2001-05-18 EP EP01304422A patent/EP1157726A1/en not_active Withdrawn
- 2001-05-22 PA PA20018517001A patent/PA8517001A1/es unknown
- 2001-05-22 IS IS5950A patent/IS5950A/is unknown
- 2001-05-23 DZ DZ010035A patent/DZ3075A1/xx active
- 2001-05-23 ZA ZA200104207A patent/ZA200104207B/xx unknown
- 2001-05-23 JP JP2001153592A patent/JP2002028475A/ja active Pending
- 2001-05-23 US US09/863,492 patent/US6558435B2/en not_active Expired - Fee Related
- 2001-05-23 AR ARP010102465A patent/AR029099A1/es active IP Right Grant
- 2001-05-23 OA OA1200100131A patent/OA11719A/en unknown
- 2001-05-23 ID IDP00200100408D patent/ID30368A/id unknown
- 2001-05-23 MA MA26212A patent/MA25321A1/fr unknown
- 2001-05-23 TN TNTNSN01075A patent/TNSN01075A1/fr unknown
- 2001-05-24 CA CA002349136A patent/CA2349136A1/en not_active Abandoned
- 2001-05-24 HR HR20010399A patent/HRP20010399A2/hr not_active Application Discontinuation
- 2001-05-24 TR TR2001/01453A patent/TR200101453A3/tr unknown
- 2001-05-24 GT GT200100095A patent/GT200100095A/es unknown
- 2001-05-24 PE PE2001000480A patent/PE20020149A1/es not_active Application Discontinuation
- 2001-05-24 SV SV2001000464A patent/SV2001000464A/es not_active Application Discontinuation
- 2001-05-24 EC EC2001004083A patent/ECSP014083A/es unknown
- 2001-05-24 AP APAP/P/2001/002151A patent/AP1321A/en active
- 2001-05-25 EA EA200100473A patent/EA003261B1/ru not_active IP Right Cessation
- 2001-05-25 CN CNB011190558A patent/CN1183989C/zh not_active Expired - Fee Related
- 2001-05-25 KR KR10-2001-0028856A patent/KR100408949B1/ko not_active IP Right Cessation
- 2001-05-25 AU AU48056/01A patent/AU775613B2/en not_active Ceased
- 2001-05-25 PL PL01347736A patent/PL347736A1/xx not_active Application Discontinuation
- 2001-05-25 EE EEP200100284A patent/EE200100284A/xx unknown
- 2001-05-25 NZ NZ511966A patent/NZ511966A/xx unknown
- 2001-05-25 SG SG200103136A patent/SG96223A1/en unknown
- 2001-05-25 GE GEAP20015914A patent/GEP20043173B/en unknown
- 2001-05-25 NO NO20012571A patent/NO20012571L/no not_active Application Discontinuation
- 2001-05-25 BR BR0102129-0A patent/BR0102129A/pt not_active IP Right Cessation
-
2002
- 2002-01-23 HK HK02100512.7A patent/HK1038896B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20010399A2 (en) | Reactive crystallization method to improve particle size | |
| RU2339364C2 (ru) | Способ затвердевания с применением антирастворителя | |
| US6960256B2 (en) | Formation of small crystals | |
| EP1077760B1 (en) | Methods and apparatus for particle formation | |
| JPH04231960A (ja) | 結晶の構造および大きさを改良する結晶化方法 | |
| IL175008A (en) | A process for making sterile nitrate aripiprazole with a small particle size and a narrow particle size distribution | |
| AU2002307907A1 (en) | Formation of small crystals | |
| Careno et al. | Drug recrystallization using supercritical anti-solvent (SAS) process with impinging jets: Effect of process parameters | |
| CN201260790Y (zh) | 一种内循环旋转填充床超重力场装置 | |
| Ambrus et al. | Effect of sonocrystallization on the habit and structure of gemfibrozil crystals | |
| CN105693734B (zh) | 一种特质ε-HNIW晶体及其制备方法 | |
| Bukovec et al. | Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties | |
| Wu et al. | Nanocrystals: The preparation, precise control and application toward the pharmaceutics and food industry | |
| US20040098839A1 (en) | Crystallization method and apparatus using an impinging plate assembly | |
| CN101721312A (zh) | 一种纳微结构药物颗粒的制备方法及装置 | |
| Murillo-Cremaes et al. | Preparation and study of naproxen in silica and lipid/polymer hybrid composites | |
| MXPA01005310A (en) | Reactive crystallization method to improve particle size | |
| Tari | Crystal habit optimization by means of impinging jet crystallization method | |
| EP2204230A1 (en) | Method for preparation of particles | |
| CN117447714A (zh) | 纳米级铜基金属有机骨架材料的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040407 Year of fee payment: 4 |
|
| OBST | Application withdrawn |